SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
Edwards Lifesciences gains attention after fresh valve data as structural heart devices, valuation debate, and healthcare ...
Data on valve durability with transcatheter aortic valve replacement are reassuring at 7 years, with implications for ...
In mostly women with small aortic annuli, self-expanding valves maintained superior hemodynamics and far lower valve ...
Kauvery Hospital, Alwarpet, has successfully treated two failing heart valves in a patient without repeat open-heart surgery, ...
Kauvery Hospital, Alwarpet, has successfully treated two failing heart valves in a patient without repeat open-heart surgery, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results